ECO2025: Heart Health Benefits Start Early with Semaglutide

At ECO2025 today, a new analysis from the landmark SELECT trial reveals that heart health benefits with semaglutide can start early for people with obesity and pre-existing heart disease. Within just three months, semaglutide reduced the risk of major cardiovascular events (MACE) by 38% compared to placebo. By six months, this risk dropped by 41%. This is happening even before significant weight loss.

The results challenge typical expectations that health improvements from obesity treatment hinge on weight loss alone. Most participants in this secondary analysis had not yet reached the full therapeutic dose of 2.4 mg semaglutide, nor had they experienced major weight changes. Yet, substantial heart health benefits were already evident.

Mechanisms Beyond Weight Loss

“This early effect suggests semaglutide may be acting through mechanisms beyond weight,” explained Dr. Jorge Plutzky, lead author and Director of Preventive Cardiology at Brigham and Women’s Hospital. Potential pathways include reductions in inflammation, blood sugar, and blood pressure. Other possibilities are early shifts in dietary patterns that therapy prompts and direct benefits to blood vessels and cardiac tissue.

The SELECT trial, enrolling over 17,000 participants globally, was not a weight loss trial. It included no dietary or behavioral interventions, and yet the cardiovascular benefit was clear. Every participant had a history of cardiovascular disease and was already taking standard heart medications – meaning semaglutide delivered added protection.

Shifting the Focus

These findings underscore a vital shift in our thinking about obesity care. Rather than focusing solely on pounds lost, we are learning that the real value lies in measurable improvements to health. Reducing heart attacks and strokes matters far more than the number on the scale.

Weight loss can be a meaningful part of treatment, but as SELECT shows, it’s not the only path to better health.

Click here for the research abstract presented today at ECO2025 on heart health benefits with semaglutide. For further perspective, click here.

Santa Iglesia Catedral Basílica de la Encarnación de Málaga, photograph by Ted Kyle / Conscienhealth

Subscribe by email to follow the accumulating evidence and observations that shape our view of health, obesity, and policy.

May 13, 2025